| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000018764 |
| Receipt No. | R000021708 |
| Official scientific title of the study | Clinical implications of DNA analysis on ADPKD |
| Date of disclosure of the study information | 2015/08/22 |
| Last modified on | 2019/02/26 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Clinical implications of DNA analysis on ADPKD
|
|
| Title of the study (Brief title) | DNAPKD study | |
| Region |
|
|
| Condition | |||
| Condition | Autosomal Dominant Polycystic Kidney Disease | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | YES | ||
| Objectives | |
| Narrative objectives1 | Mutation types of PKD1 and PKD2 are re-classified according to the effect on polycystin 1 and 2 structures. Then the relationships between new classification and clinical indices are examined. |
| Basic objectives2 | Bio-equivalence |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | The relationship between mutational type and phenotype. |
| Key secondary outcomes | The efficacy of next generation sequencing method |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Autosomal Dominant Polycystic Kidney Disease | |||
| Key exclusion criteria | The patients who do not consent. | |||
| Target sample size | 85 | |||
| Research contact person | |
| Name of lead principal investigator | Eiji Higashihara |
| Organization | Kyorin University School of Medicine |
| Division name | ADPKD Research |
| Address | 6-20-2 Shinkawa, Mitaka, Tokyo |
| TEL | 0422-49-7428 |
| ehigashi@ks.kyorin-u.ac.jp | |
| Public contact | |
| Name of contact person | Fumie Kobayashi |
| Organization | Research Promoting Center |
| Division name | Kyorin University Research Promoting Center |
| Address | 6-20-2 Shinkawa, Mitaka, Tokyo |
| TEL | 0422-47-5511 |
| Homepage URL | http://www.kyorin-u.ac.jp/univ/society/study/ |
| kenkyushien@ks.kyorin-u.ac.jp | |
| Sponsor | |
| Institute | ADPKD Research section, Kyorin University, School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Otsuka Pharmaceutical Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Otsuka Pharmaceutical Co., Ltd. |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | 1)Kinoshita M, Higashihara E, Kawano H, Higashiyama R, Koga D, Fukui T, Gondo N, Oka T, Kawahara K, Rigo K, Hague T, Katsuragi K, Sudo K, Takeshi M, Horie S, Nutahara K. Technical evaluation: Identification of pathogenic mutations in PKD1 and PKD2 in patients with autosomal dominant polycystic kidney disease by next-generation sequencing and use of a comprehensive new classification system. PLoS One. 11: e0166288. 2016.
2)Higashihara E, Horie S, Kinoshita M, Harris P, Okegawa T, Tanbo M, Hara H, Yamaguchi T, Shigemori K, Kawano H, Miyazaki I, Kaname S, Nutahara K. A potentially crucial role of the PKD1 C terminal tail in renal prognosis. Clin Exp Nephrol. 22: 395-404. 2017. |
| Other related information | N/A |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021708 |